Article

What Is the Incidence, Prevalence, and Natural History of Indeterminate Colitis?

Department of Gastroenterology, Ospedale Generale di Zona Valduce, Como, Italy.
Inflammatory Bowel Diseases (Impact Factor: 4.46). 10/2008; 14 Suppl 2(Supplement):S159-60. DOI: 10.1002/ibd.20594
Source: PubMed
Download full-text

Full-text

Available from: Gianmichele Meucci, Nov 20, 2014
  • Source

    Preview · Article · Feb 2009 · Expert Review of Molecular Diagnostics
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unfortunately, clinicians do not yet have a definitive serologic test for the diagnosis of UC. Instead, a suspected diagnosis of UC must be confirmed with endoscopic and histologic mucosal findings. These findings must be considered in conjunction with pathogen testing to exclude the possibility of infectious colitis. In addition, clinicians must evaluate patients for a history of exposure to environmental factors that might explain the observed inflammation (such as ischemia, radiation, or drugs) as well as for conditions in which colitis is caused by some other etiology (such as solitary rectal ulcer syndrome or segmental colitis with diverticulitis). Endoscopy, radiology, and histology remain the mainstays of our clinical diagnostic armamentarium. Microscopic findings and disease distribution help to classify patients as having UC, CD, or indeterminate colitis.
    No preview · Article · May 2011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Accurate diagnosis of inflammatory bowel disease (IBD) and differentiation between its two major subtypes, Crohn's disease (CD) and ulcerative colitis (UC), are crucial for planning optimum treatment strategies. However, as these related diseases share many pathological, histological and serological features, their differential diagnosis can be difficult in practice. We have been able to identify seven biomarkers which, following further evaluation, proved to be very effective in discriminating UC from CD and excluding irritable bowel syndrome. These biomarkers and a specially developed algorithm were incorporated into a quantitative polymerase chain reaction (qPCR)-based diagnostic test launched on the Swedish market in 2009 under the tradename DiBiCol® (InDex Pharmaceuticals AB, Stockholm). DiBiCol allows to quickly and reliably determine the correct IBD subtype, thereby ensuring a more appropriate treatment of patients.
    No preview · Article · Jan 2012 · European Gastroenterology and Hepatology Review
Show more